Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: Potential clinical implications

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 141-149

  Weimert, Nicole A ^a   DeRotte, Maurits ^b   Alloway, Rita R ^c   Woodle, E Steve ^d   Vinks, Alexander A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Enteric caoted mycophenolate; Inosine monophosphate dehydrogenase; Mycophenolate mofetil; Mycophenolic acid

Indexed keywords

CALCINEURIN; CYCLOSPORIN; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

BLOOD SAMPLING; COMPARATIVE STUDY; DRUG EXPOSURE; DRUG MONITORING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION;

EID: 34248158954     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31803d37b6     Document Type: Review

References (74)

1. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm. 1997;54:285-294.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-232.
3. Group EMMCS. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
4. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122-1124.
5. Chinyu S, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am. 2004;33:209-234.
6. Port FK, Dykstra DM, Merion RM, et al. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant. 2004;5:843-849.
7. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration curve for total, but not for free, mycophenolic acid increases in stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit. 1999;21:491.
8. Kuypers DRJ, Vanrenterghen Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolic mofetil. Ther Drug Monit. 2003;25:609-622.
9. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001;34:17-22.
10. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
11. Lu YP, Lin B, Liang MZ, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in Chinese kidney transplant recipients treated with mycophenolate mofetil. Transplant Proc. 2004;36:2079-2081.
12. Pisupati J, Jain A, Burckart G, et al. Intraindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol. 2005;45:34-41.
13. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2004;59:271-280.
14. Catteno D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant. 2004;4:299-310.
15. Staatz CE, Duffull SB, Kiberd B, et al. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol. 2005;61:507-516.
16. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
17. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: a report of roundtable discussion. Ther Drug Monit. 2001;23:305-315.
18. Van Gelder T, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
19. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
20. Papageorgiou C. Enterohepatic recirculation a powerful incentive for drug discovery in inosine monophosphate dehydrogenase field. Mini Rev Med Chem. 2001;1:71-77.
21. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2004;33:139-146.
22. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005;78:317-321.
23. Kuypers DRJ, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronyl-transferase 1A9 (UGT1A9) gene promoter region single nucleotide polymorphisms T275A and C2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
24. Bullingham RES, Nicholls AJ, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
25. Shum B, Duffull SB, Taylor PJ, et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56:188-197.
26. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-425.
27. van Hest RM, van Gelder T, Vulto AG, et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083-1096.
28. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminaemia. Ther Drug Monit. 2004;26:284-286.
29. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
30. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leucopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129.
31. Buchler M, Lebranchu Y, Beneton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther. 2005;78:34-42.
32. El Haggan W, Ficheux M, Debruyne D, et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. Transplant Proc. 2005;37:864-866.
33. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
34. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2002;40:624-633.
35. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501-515.
36. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl-glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
37. Gummert JF, Barten MJ, Sherwood SW, et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther. 1999;291:1100-1112.
38. Barten MJ, van Gelder T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant. 2002;2:719-732.
39. Hohage H, Zeh M, Heck M, et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc. 2005;37:1748.
40. Zimmerman A, Jing JG, Spychala J, et al. Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Advan Enzyme Regul. 1996;36:75-84.
41. Mcphillips CC, Hyle JW, Reines D. Detection of the mycophenolate- inhibited form of IMP dehydrogenase in vivo. PNAS. 2004;101:12171-12176.
42. Blaheta RA, Leckel K, Wittig B, et al. Inhibition of endothelial receptor expression and T-cell ligand activity by mycophenolate mofetil. Transpl Immunol. 1998;6:251-259.
43. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and II isoforms in human leukocytes. Biochem Pharmacol. 2004;67:767-776.
44. Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265:5292-5295.
45. Saunders JO, Raybuck SA. Inosine monophosphate dehydrogenase: consideration of structure, kinetics, and therapeutic potential. Annu Rep Med Chem. 2000;35:201-210.
46. Huberman E, Glesne D, Collart F. Regulation of IMP dehydrogenase in humans and other species. Clin Biochem. 1997;30:260-261.
47. Ji Y, Gu J, Makhov AM, et al. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem. 2006;281:206-212.
48. Zimmerman A, Jing JG, Spychala J, et al. Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes. Advan Enzyme Regul. 1996;36:75-84.
49. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and II isoforms in human leukocytes. Biochem Pharmacol. 2004;67:767-776.
50. Gu JJ, Stegmann S, Gathy K, et al. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest. 2000;106:599-606.
51. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
52. Pankiewicz KW, Patterson SE, Black PL, et al. Cofactor mimics as selective inhibitors of NAD dependent inosine monophosphate dehydrogenase (IMPDH) the major therapeutic target. Curr Med Chem. 2004;11:887-900.
53. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit. 1997;19:358-460.
54. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22:20-26.
55. Budde K, Glander P, Braun KP, et al. Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. Transplant Proc. 2001;33:3313-3315.
56. Langman LJ, Hiroyuki N, Thliveris JA, et al. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit. 1997;19:146-152.
57. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
58. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem. 1995;41:295-299.
59. Vethe NT, Mandla R, Line PD, et al. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest. 2006;66:31-44.
60. Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Clin Biochem. 1994;27:206.
61. Langman LJ, Hiroyuki N, Thliveris JA, et al. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit. 1997;19:146-152.
62. Albrecht W, Storck M, Pfetsch E, et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit. 2000;22:283-294.
63. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549.
64. Budde K, Braun KP, Glander P. Pharmacodynamic monitoring of mycophenolate mofetil in, et al stable renal allograft recipients. Transplant Proc. 2002;34:1748-1750.
65. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476.
66. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcomes after renal transplantation. Am J Transplant. 2004;4:2045-2051.
67. Budde K, Glander P, Braun KP, et al. Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. Transplant Proc. 2001;33:3313-3315.
68. Daxecker H, Raab M, Muller MM. Influence of mycophenolic acid on inosine 5# monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. Clin Chim Acta. 2002;318:71-77.
69. Vannozzi F, Filipponi F, Di Paolo R, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004;36:2787-2790.
70. Catteno D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant. 2004;4:299-310.
71. Budde K, Glander P. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid. A CME Monograph. Stamford, MA: International Meetings & Science Inc; May 2004.
72. Storck M, Abendroth D, Albrecht W, et al. IMPDH activity in whole blood and isolated blood cell fraction for monitoring of Cellcept mediated immunosuppression. Transplant Proc. 1999;31:1115-1116.
73. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
74. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcomes after renal transplantation. Am J Transplant. 2004;4:2045-2051.